Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.

Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...

Financial writer reports activist investor Starboard Value's stake in Kenvue Inc., seeking measures to boost stock price.

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...